Search Result
Results for "
Thromboembolic
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15799
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
|
-
-
- HY-137431A
-
|
(R)-BAY-2433334
|
Others
|
Cardiovascular Disease
|
|
(R)-Asundexian ((R)-BAY-2433334) is the enantiomer of Asundexian (HY-137431). (R)-Asundexian can be used in studies of cardiovascular disease (especially thrombotic or thromboembolic disease), edema, and ophthalmic disease .
|
-
-
- HY-101918
-
|
|
Others
|
Cardiovascular Disease
|
|
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases .
|
-
-
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
-
-
- HY-10264
-
|
DU-176
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
|
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
|
-
-
- HY-10264B
-
|
DU-176b monohydrate
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
|
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
|
-
-
- HY-10264A
-
|
DU-176b
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
|
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
|
-
-
- HY-10758
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .
|
-
-
- HY-10264C
-
|
DU-176 hydrochloride
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
|
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
|
-
-
- HY-163347
-
|
|
Others
|
Cardiovascular Disease
|
|
FXIIa-IN-3 (Compound 8) is a potent and selective Factor XIIa (FXIIa) inhibitor, with an IC50 of 0.045 μM. FXIIa-IN-3 also exhibits a substantial margin of selectivity against related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 can be used for the research of thromboembolic diseases .
|
-
-
- HY-10264R
-
|
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
|
Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
|
-
-
- HY-111755
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
|
-
-
- HY-W854549
-
|
Fondaparinux free acid
|
Factor Xa
|
Cardiovascular Disease
|
|
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .
|
-
-
- HY-100655
-
|
|
Drug Metabolite
|
Cardiovascular Disease
|
|
O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
|
-
-
- HY-163348
-
|
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
|
FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant .
|
-
-
- HY-100655R
-
|
|
Drug Metabolite
|
Cardiovascular Disease
|
|
O-Desmethyl apixaban (Standard) is the analytical standard of O-Desmethyl apixaban. This product is intended for research and analytical applications. O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
|
-
-
- HY-10273
-
|
AZD0837; Atecegatran fexenetil
|
Thrombin
|
Cardiovascular Disease
|
|
Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct thrombin inhibitor.
|
-
-
- HY-B0366A
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
|
-
-
- HY-B1622
-
-
-
- HY-50667
-
Apixaban
Maximum Cited Publications
10 Publications Verification
BMS-562247-01
|
Factor Xa
|
Cardiovascular Disease
Cancer
|
|
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
-
- HY-125615
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
Others
|
|
DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
|
-
-
- HY-B1622R
-
|
|
5-HT Receptor
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Cyproheptadine (Standard) is the analytical standard of Cyproheptadine. This product is intended for research and analytical applications. Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .
|
-
-
- HY-B0366AR
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Cyproheptadine (hydrochloride) (Standard) is the analytical standard of Cyproheptadine (hydrochloride). This product is intended for research and analytical applications. Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
|
-
-
- HY-50667R
-
|
|
Factor Xa
|
Cardiovascular Disease
Cancer
|
|
Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
-
- HY-W091734
-
|
|
Amino Acid Derivatives
|
Cardiovascular Disease
Neurological Disease
|
|
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .
|
-
-
- HY-50667S1
-
|
BMS-562247-01-d3
|
Isotope-Labeled Compounds
|
Others
|
|
Apixaban-d3 (BMS-562247-01-d3)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
-
- HY-10275
-
|
AR-H067637
|
Thrombin
|
Cardiovascular Disease
|
|
Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders .
|
-
-
- HY-150682
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .
|
-
-
- HY-10264S
-
|
DU-176-d6
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
-
- HY-D0837
-
|
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
|
Ser/Thr Protease
Thrombopoietin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
-
- HY-D0837R
-
|
|
Ser/Thr Protease
Thrombopoietin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D0837
-
|
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
|
Cell Assay Reagents
|
|
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
- HY-W854549
-
|
Fondaparinux free acid
|
Carbohydrates
|
|
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .
|
-
- HY-D0837R
-
|
|
Cell Assay Reagents
|
|
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W091734
-
|
|
Amino Acid Derivatives
|
Cardiovascular Disease
Neurological Disease
|
|
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10264S
-
|
|
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
-
- HY-50667S1
-
|
|
|
Apixaban-d3 (BMS-562247-01-d3)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
